Immunovant (IMVT)
(Delayed Data from NSDQ)
$15.40 USD
+0.29 (1.92%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $15.44 +0.04 (0.26%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Immunovant, Inc. has a market cap of $2.68B, which represents its share price of $15.40 multiplied by its outstanding shares number of 174.32M. As a mid-cap company, IMVT's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
IMVT 15.40 +0.29(1.92%)
Will IMVT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IMVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMVT
Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
IMVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy
Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?
Other News for IMVT
NR7 appears for IMVT after 1.92% move
Is IMVT building bearish momentum? 20 Day Moving Average Resistance shows up after declining 1.18%
IMVT forms 20 Day Moving Average Resistance on September 16
Is IMVT primed for downward momentum? Fell Below 20 Day Moving Average shows up after sinking 3.9%
Tracking Baker Brothers Portfolio - Q2 2025 Update